CNBX Company Profile and Key Details
CNBX Pharmaceuticals
Price Chart
Stock Price Today
CNBX Pharmaceuticals Inc. (CNBX) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.00 during the session.
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2.76M |
| Sep 10, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.6M |
| Sep 09, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2.68M |
| Sep 08, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 34.57M |
| Sep 04, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2M |
| Sep 03, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 42 |
| Sep 02, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M |
| Sep 01, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 525.56K |
| Aug 28, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 225K |
| Aug 27, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 5.77M |
| Aug 26, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 10.71M |
| Aug 25, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 504.94K |
| Aug 21, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 80.02K |
| Aug 20, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99M |
| Aug 19, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2.24M |
| Aug 18, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 30K |
| Aug 17, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 209.06K |
| Aug 14, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 10K |
| Aug 13, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 15 |
| Aug 12, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 20.02K |
Contact Details
About Company
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
Company Information
| Employees | 1 |
| Beta | 0.76 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | August |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Pres, Chief Operating Officer & Executive Chairman
Dr. Sanja Goldberg
Chief Technology Officer
Mr. Eyal Barad
Co-Founder, Chief Executive Officer & Director
Noam Permont
Vice President of PR & Investor Relations
Mr. Yasha Borstein
Chief Data Officer
Dr. Ilya Reznik M.D.
Head of Neuropsychiatry Devel.
Dr. Yaakov Waksman
Head of Cannabidiol Research
Dr. Tal Mofkadi Ph.D.
Financial Advisor & Member of Advisory Board
Dr. Sigalit Ariely-Portnoy Ph.D.
Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA
Chief Financial Officer
Mr. Uri Ben-Or C.P.A., CPA, M.B.A., MBA
Chief Financial Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep